Vuong Trieu, PhD
|Founder of IgDraSol and Biomiga Diagnostics. Led the development of Cynviloq, Abraxane, nab-docetaxel, nab-rapamycin, nab-17-AAG, nab-IDN5404 at Abraxis (Celgene acquired Abraxis for $2.9 billion). Repositioned Genexol-PM from Korea into a viable product for US market as Abraxane equivalent and as drug-device combination therapy at IgDraSol|
Fatih Uckun, MD PhD
|Dr. Uckun is an elected Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations. He received numerous awards for his work on monoclonal antibodies, recombinant cytokines and fusion proteins, radiation sensitizers, kinase inhibitors and targeted therapeutics for difficult-to-treat cancers, including the Stohlman Memorial Award of the Leukemia Society of America, the highest honor given to a Leukemia Society Scholar. He has published more than 500 peer-reviewed papers, authored numerous review articles and book chapters and and is an inventor on numerous patents.Dr. Uckun earned his doctoral degrees at the University of Heidelberg, Germany.
Dr. Uckun worked as a Professor of Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota (1986-1997), where he became the first recipient of the Endowed Hughes Chair in Biotherapy, and as a Professor of Pediatrics and Head of Translational Research in Leukemia and Lymphoma of the Children’s Center for Cancer and Blood Diseases at the University of Southern California (2009-2015). From 2012-2015, Dr. Uckun served as chair of the Biotargeting Working Group and a Member of the Coordination and Governance Committee of the NCI Alliance for Nanotechnology in Cancer. Prior to joining Oncotelic, Dr. Uckun served as Head of Immuno-Oncology at Ares Pharmaceuticals and Executive Medical Director and Strategy Lead in Global Oncology and Hematology at Syneos Health. Prior to this, he was Vice President of Research and Clinical Development at Nantkwest, Chief Scientific Officer of Jupiter Research Institute and, before that, held senior-level scientific and research positions at Parker Hughes Institute and its cancer center, Paradigm Pharmaceuticals, and the Children’s Cancer Study Group.
Larn Hwang, PhD
|Drug developer veteran with broad expertise in drug discovery and biomarker development. Key strength on drug discovery/development, clinical and regulatory operations. Led the team through a successful EOP2 meeting and FPI within 4 months of protocol. Founder of IgDraSol and Biomiga Diagnostics.
J&J, ABI, Celgene, IgDraSol, Biomiga Diagnostics, Sorrento Therapeutics
Chulho Park, PhD
|Recognized pharmaceutical leader in Korea with strong business development background. Extensive experience in mAb process development. CEO and Founder of MabPrex. Led the pharmaceutical development of therapeutic antibodies as well as small molecule drugs. President of Pharmaceutical Development at Igdrasol. Led the CMC development at IgDraSol bringing manufacturing of the drug product to US FDA standard.
Eli Lilly, AME, aTyr, MabPrex, IgDraSol